Changsha, Hunan, China – August 15, 2026 – Molecular Diagnostics Industry Moves Toward Faster, More Accessible TestingThe global molecular diagnostics industry is entering a new phase of development, driven by increasing demand for rapid testing, decentralized healthcare, and precision medicine.Traditional laboratory testing models are gradually evolving toward faster and more flexible diagnostic workflows. Technologies including PCR, real-time PCR, isothermal amplification, and next-generation sequencing are becoming increasingly important in infectious disease detection, genetic analysis, and personalized healthcare.Industry reports indicate continued growth in the molecular diagnostics sector, supported by expanding applications in genomic testing, oncology, infectious disease monitoring, and decentralized diagnostics.Three Key Trends Shaping Molecular Diagnostics1. From Central Laboratories to Decentralized TestingOne of the most significant changes is the movement of molecular testing closer to patients.Point-of-care molecular diagnostics are gaining attention because they can reduce testing time and improve access in hospitals, clinics, and resource-limited regions.This trend is increasing demand for:
2. Higher Demand for Multiplex DetectionModern healthcare increasingly requires the ability to detect multiple targets simultaneously.Multiplex PCR and advanced molecular platforms allow researchers and clinicians to analyze several biomarkers within a single workflow.Applications include:
3. Integration of Molecular Testing with GenomicsThe relationship between molecular diagnostics and sequencing technologies is becoming increasingly connected.NGS-based workflows continue expanding into clinical research, precision medicine, and pharmaceutical development, creating demand for high-quality enzymes, reagents, and optimized molecular biology solutions.Looking AheadThe future of molecular diagnostics will depend on improving three key factors:AccuracySpeedAccessibilityAs diagnostic technologies continue evolving, reliable molecular reagents and enzyme solutions will remain essential components supporting innovation across healthcare and life science research.
About us
Hyasen Biotech is engaged in research, production and sales of in-vitro Diagnostic core enzymes & reagents, Biopharma enzymes materials, Active Pharmaceutical Ingridents, Laboratory equipment and testing instruments.
Media ContactCompany Name: Hyasen Biotechnology Co., Ltd.Contact Person: Media RelationsEmail: Send EmailCountry: ChinaWebsite: https://www.hyasen.com/
